Cargando…

Sustained elevation of soluble B- and T- lymphocyte attenuator predicts long-term mortality in patients with bacteremia and sepsis

Soluble B and T lymphocyte attenuator (sBTLA) has been shown to be associated with severity and outcome, in critically ill septic patients. We aimed to assess the dynamic expression of sBTLA, as a prognostic biomarker of long-term mortality in patients with bloodstream infection (BSI) and sepsis, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Lange, Anna, Cajander, Sara, Magnuson, Anders, Strålin, Kristoffer, Hultgren, Olof
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936450/
https://www.ncbi.nlm.nih.gov/pubmed/35312715
http://dx.doi.org/10.1371/journal.pone.0265818
_version_ 1784672221141139456
author Lange, Anna
Cajander, Sara
Magnuson, Anders
Strålin, Kristoffer
Hultgren, Olof
author_facet Lange, Anna
Cajander, Sara
Magnuson, Anders
Strålin, Kristoffer
Hultgren, Olof
author_sort Lange, Anna
collection PubMed
description Soluble B and T lymphocyte attenuator (sBTLA) has been shown to be associated with severity and outcome, in critically ill septic patients. We aimed to assess the dynamic expression of sBTLA, as a prognostic biomarker of long-term mortality in patients with bloodstream infection (BSI) and sepsis, and to evaluate its association with biomarkers indicative of inflammation and immune dysregulation. Secondarily, sBTLA was evaluated in association with severity and bacterial etiology. Patients with BSI (n = 108) were prospectively included, and serially sampled from admission to day 28. Blood and plasma donors (n = 31), sampled twice 28 days apart, served as controls. sBTLA concentration in plasma was determined with enzyme-linked immunosorbent assay. Associations between sBTLA on day 1–2 and 7, and mortality at 90 days and 1 year, were determined with unadjusted, and adjusted Cox regression. Differences related to severity was assessed with linear regression. Mixed model was used to assess sBTLA dynamics over time, and sBTLA associations with bacterial etiology and other biomarkers. sBTLA on day 1–2 and 7 was associated with mortality, in particular failure to normalize sBTLA by day 7 was associated with an increased risk of death before day 90, adjusted HR 17 (95% CI 1.8–160), and one year, adjusted HR 15 (95% CI 2.8–76). sBTLA was positively associated with CRP, and negatively with lymphocyte count. sBTLA on day 1–2 was not linearly associated with baseline SOFA score increase. High SOFA (≥4) was however associated with higher mean sBTLA than SOFA ≤3. sBTLA was not associated with bacterial etiology. We show that sustained elevation of sBTLA one week after hospital admission is associated with late mortality in patients with BSI and sepsis, and that sBTLA concentration is associated with CRP and decreased lymphocyte count. This suggests that sBTLA might be an indicator of sustained immune-dysregulation, and a prognostic tool in sepsis.
format Online
Article
Text
id pubmed-8936450
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-89364502022-03-22 Sustained elevation of soluble B- and T- lymphocyte attenuator predicts long-term mortality in patients with bacteremia and sepsis Lange, Anna Cajander, Sara Magnuson, Anders Strålin, Kristoffer Hultgren, Olof PLoS One Research Article Soluble B and T lymphocyte attenuator (sBTLA) has been shown to be associated with severity and outcome, in critically ill septic patients. We aimed to assess the dynamic expression of sBTLA, as a prognostic biomarker of long-term mortality in patients with bloodstream infection (BSI) and sepsis, and to evaluate its association with biomarkers indicative of inflammation and immune dysregulation. Secondarily, sBTLA was evaluated in association with severity and bacterial etiology. Patients with BSI (n = 108) were prospectively included, and serially sampled from admission to day 28. Blood and plasma donors (n = 31), sampled twice 28 days apart, served as controls. sBTLA concentration in plasma was determined with enzyme-linked immunosorbent assay. Associations between sBTLA on day 1–2 and 7, and mortality at 90 days and 1 year, were determined with unadjusted, and adjusted Cox regression. Differences related to severity was assessed with linear regression. Mixed model was used to assess sBTLA dynamics over time, and sBTLA associations with bacterial etiology and other biomarkers. sBTLA on day 1–2 and 7 was associated with mortality, in particular failure to normalize sBTLA by day 7 was associated with an increased risk of death before day 90, adjusted HR 17 (95% CI 1.8–160), and one year, adjusted HR 15 (95% CI 2.8–76). sBTLA was positively associated with CRP, and negatively with lymphocyte count. sBTLA on day 1–2 was not linearly associated with baseline SOFA score increase. High SOFA (≥4) was however associated with higher mean sBTLA than SOFA ≤3. sBTLA was not associated with bacterial etiology. We show that sustained elevation of sBTLA one week after hospital admission is associated with late mortality in patients with BSI and sepsis, and that sBTLA concentration is associated with CRP and decreased lymphocyte count. This suggests that sBTLA might be an indicator of sustained immune-dysregulation, and a prognostic tool in sepsis. Public Library of Science 2022-03-21 /pmc/articles/PMC8936450/ /pubmed/35312715 http://dx.doi.org/10.1371/journal.pone.0265818 Text en © 2022 Lange et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Lange, Anna
Cajander, Sara
Magnuson, Anders
Strålin, Kristoffer
Hultgren, Olof
Sustained elevation of soluble B- and T- lymphocyte attenuator predicts long-term mortality in patients with bacteremia and sepsis
title Sustained elevation of soluble B- and T- lymphocyte attenuator predicts long-term mortality in patients with bacteremia and sepsis
title_full Sustained elevation of soluble B- and T- lymphocyte attenuator predicts long-term mortality in patients with bacteremia and sepsis
title_fullStr Sustained elevation of soluble B- and T- lymphocyte attenuator predicts long-term mortality in patients with bacteremia and sepsis
title_full_unstemmed Sustained elevation of soluble B- and T- lymphocyte attenuator predicts long-term mortality in patients with bacteremia and sepsis
title_short Sustained elevation of soluble B- and T- lymphocyte attenuator predicts long-term mortality in patients with bacteremia and sepsis
title_sort sustained elevation of soluble b- and t- lymphocyte attenuator predicts long-term mortality in patients with bacteremia and sepsis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936450/
https://www.ncbi.nlm.nih.gov/pubmed/35312715
http://dx.doi.org/10.1371/journal.pone.0265818
work_keys_str_mv AT langeanna sustainedelevationofsolublebandtlymphocyteattenuatorpredictslongtermmortalityinpatientswithbacteremiaandsepsis
AT cajandersara sustainedelevationofsolublebandtlymphocyteattenuatorpredictslongtermmortalityinpatientswithbacteremiaandsepsis
AT magnusonanders sustainedelevationofsolublebandtlymphocyteattenuatorpredictslongtermmortalityinpatientswithbacteremiaandsepsis
AT stralinkristoffer sustainedelevationofsolublebandtlymphocyteattenuatorpredictslongtermmortalityinpatientswithbacteremiaandsepsis
AT hultgrenolof sustainedelevationofsolublebandtlymphocyteattenuatorpredictslongtermmortalityinpatientswithbacteremiaandsepsis